A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma
Clinical trial NCT02076646 · UNKNOWN
Trial details
- NCT number
- NCT02076646
- Sponsor
- Philogen S.p.A.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-07-31
- Primary completion
- 2016-05-17
- Enrollment
- 96
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.